Equillium Inc (EQ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $106.20M
Last updated: Nov 17, 2026 at 11:05 AM ET
Equillium Inc (EQ) Competitors
The companies most similar to Equillium are Immunic (IMUX), ImmuCell (ICCC) and Eledon Pharmaceuticals (ELDN). By market cap, Equillium ranks 4th of the 13 companies on this page; Immuneering (IMRX) is the largest at $240.27M.
Peer Comparison
EQ's revenue growth of -52.3% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Equillium (EQ) | $106.20M | N/A | 29.3x | 0.0% | N/A | -52.3% | 0.00% |
| Immunic Inc (IMUX) | $102.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| ImmuCell Corporation (ICCC) | $97.73M | 57.2x | 3.1x | 2.6% | 4.6% | 11.5% | 0.00% |
| Eledon Pharmaceuticals Inc (ELDN) | $178.63M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cellectis SA (CLLS) | $118.86M | N/A | 1.8x | 0.0% | -74.1% | -85.4% | 0.00% |
| Coherus BioSciences Inc (CHRS) | $81.21M | N/A | 1.5x | -253.4% | -144.8% | 23.4% | 0.00% |
| OUTLOOK THERAPEUTICS INC (OTLK) | $100.54M | N/A | N/A | 0.0% | -776.9% | -99.4% | 0.00% |
| Immuneering Corp (IMRX) | $240.27M | N/A | N/A | 0.0% | N/A | -99.8% | 0.00% |
| Seer Inc (SEER) | $87.63M | N/A | 5.8x | 0.0% | N/A | -3.4% | 0.00% |
| Elicio Therapeutics Inc. (ELTX) | $42.46M | N/A | N/A | 0.0% | -96.6% | 0.0% | 0.00% |
| Unicycive Therapeutics Inc (UNCY) | $97.25M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| ImageneBio, Inc. (IMA) | $43.22M | N/A | 68.5x | 0.0% | N/A | 0.0% | 0.00% |
| Anixa Biosciences Inc (ANIX) | $91.08M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $97.49M | 57.2x | 3.1x | 0.0% | -96.6% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Equillium, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Immunic Inc (IMUX) | Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune... | IMUX competitors |
| ImmuCell Corporation (ICCC) | ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle... | ICCC competitors |
| Eledon Pharmaceuticals Inc (ELDN) | Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases... | ELDN competitors |
| Cellectis SA (CLLS) | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors... | CLLS competitors |
| Coherus BioSciences Inc (CHRS) | Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. | CHRS competitors |
| OUTLOOK THERAPEUTICS INC (OTLK) | Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic... | OTLK competitors |
| Immuneering Corp (IMRX) | Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its... | IMRX competitors |
| Seer Inc (SEER) | Seer, Inc., a life sciences company, is dedicated to developing and marketing products for researchers to unlock biological information. | SEER competitors |
| Elicio Therapeutics Inc. (ELTX) | Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. | ELTX competitors |
| Unicycive Therapeutics Inc (UNCY) | Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for kidney diseases... | UNCY competitors |
| ImageneBio, Inc. (IMA) | ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. | IMA competitors |
| Anixa Biosciences Inc (ANIX) | Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. | ANIX competitors |
Frequently Asked Questions About EQ
Who are Equillium's main competitors?
The companies most similar to Equillium include Immunic (IMUX), ImmuCell (ICCC), Eledon Pharmaceuticals (ELDN), Cellectis SA (CLLS) and Coherus BioSciences (CHRS), listed from the closest match.
Who is Equillium's biggest competitor?
Immuneering (IMRX) is the largest of the similar companies at $240.27M; Immunic (IMUX) is the closest match by business profile, size, sector and industry.
How does EQ stock compare with its competitors?
EQ's P/S is 29.3x against a peer median of 3.1x; its net margin is 0.0% against a peer median of 0.0%.
Which of Equillium's competitors pays a higher dividend?
Equillium pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Equillium bigger than its competitors?
No. Equillium is 4th by market cap among the 13 companies on this page; the largest is Immuneering (IMRX) at $240.27M.
EQ pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors